Exploring the experiences of cognitive symptoms in Long COVID: a mixed-methods study in the UK.

Publication date: Jan 25, 2025

To explore the lived experiences and extent of cognitive symptoms in Long COVID (LC) in a UK-based sample. This study implemented a mixed-methods design. Eight focus groups were conducted to collect qualitative data, and the Framework Analysis was used to reveal the experiences and impact of cognitive symptoms. A self-report questionnaire was used to collect the quantitative data to assess the perceived change and extent of symptomology post COVID-19. Focus groups were conducted in April 2023 online via Zoom and in-person at the University of Leeds, UK. 25 people with LC living in the UK participated in the study. Participants were aged 19-76 years (M=43. 6 years, SD=14. 7) and included 17 women and 8 men. Reduced cognitive ability was among the most prevalent symptoms reported by the study participants. Three key themes were identified from the qualitative data: (1) rich accounts of cognitive symptoms; (2) the impact on physical function and psychological well-being and (3) symptom management. Descriptions of cognitive symptoms included impairments in memory, attention, language, executive function and processing speed. Cognitive symptoms had a profound impact on physical functioning and psychological well-being, including reduced ability to work and complete activities of daily living. Strategies used for symptom management varied in effectiveness. Cognitive dysfunction in LC appears to be exacerbated by vicious cycle of withdrawal from daily life including loss of employment, physical inactivity and social isolation driving low mood, anxiety and poor cognitive functioning. Previous evidence has revealed the anatomical and physiological biomarkers in the brain affecting cognition in LC. To synthesise these contributing factors, we propose the Long-COVID Interacting Network of factors affecting Cognitive Symptoms. This framework is designed to inform clinicians and researchers to take a comprehensive approach towards LC rehabilitation, targeting the neural, individual and lifestyle factors.

Open Access PDF

Concepts Keywords
April Adult
Biomarkers Aged
Covid Cognition
Leeds Cognition
Qualitative Cognitive Dysfunction
COVID-19
COVID-19
Female
Focus Groups
Humans
Male
Middle Aged
Post-Acute COVID-19 Syndrome
PUBLIC HEALTH
Qualitative Research
QUALITATIVE RESEARCH
SARS-CoV-2
United Kingdom
Young Adult

Semantics

Type Source Name
disease MESH Long COVID
disease MESH COVID-19
disease MESH psychological well-being
disease IDO symptom
disease MESH Cognitive dysfunction
disease MESH physical inactivity
disease MESH anxiety
disease MESH lifestyle factors
disease MESH syndrome
disease MESH infection
disease MESH breathlessness
disease MESH memory deficits
drug DRUGBANK Coenzyme M
drug DRUGBANK Indoleacetic acid
disease MESH Alzheimer’s disease
disease MESH neuroinflammation
disease MESH hypoxia
disease MESH dementia
disease MESH ‘brain fog
disease MESH confusion
drug DRUGBANK Trestolone
disease MESH Chronic Pain
disease IDO process
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
drug DRUGBANK Spinosad
disease MESH mood disorders
disease MESH depression
disease MESH autoimmune response
disease MESH encephalitis
disease MESH chronic fatigue syndrome
disease MESH major depressive disorder
disease IDO intervention
pathway REACTOME Vitamins
disease IDO quality
pathway REACTOME Translation
drug DRUGBANK Guanosine
disease MESH Infectious Diseases
disease MESH AIDS
disease MESH symptom exacerbation
disease MESH Functional Status
disease MESH death
disease IDO susceptibility
disease MESH multiple sclerosis
disease MESH loneliness

Original Article

(Visited 1 times, 1 visits today)